Cargando…
Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection
SARS-CoV-2, a member of the coronavirus family, is the causative agent of the COVID-19 pandemic. Currently, there is still an urgent need in developing an efficient therapeutic intervention. In this study, we aimed at evaluating the therapeutic effect of a single intranasal treatment of the TLR3/MDA...
Autores principales: | Tamir, Hadas, Melamed, Sharon, Erez, Noam, Politi, Boaz, Yahalom-Ronen, Yfat, Achdout, Hagit, Lazar, Shlomi, Gutman, Hila, Avraham, Roy, Weiss, Shay, Paran, Nir, Israely, Tomer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878863/ https://www.ncbi.nlm.nih.gov/pubmed/35215785 http://dx.doi.org/10.3390/v14020189 |
Ejemplares similares
-
Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus
por: Vitner, Einat B., et al.
Publicado: (2021) -
TLR3 and TLR9 Agonists Improve Postexposure Vaccination Efficacy of Live Smallpox Vaccines
por: Israely, Tomer, et al.
Publicado: (2014) -
Identification of T-Cell Epitopes Using a Combined In-Silico and Experimental Approach in a Mouse Model for SARS-CoV-2
por: Erez, Noam, et al.
Publicado: (2023) -
Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization
por: Noy-Porat, Tal, et al.
Publicado: (2023) -
Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity
por: Achdout, Hagit, et al.
Publicado: (2021)